Log in to save to my catalogue

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2839248163

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, conva...

Alternative Titles

Full title

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2839248163

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2839248163

Other Identifiers

ISSN

1078-8956,1546-170X

E-ISSN

1546-170X

DOI

10.1038/s41591-023-02480-8

How to access this item